Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease. The French drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results